Ferrostatin-1 Targets Mitochondrial Function to Improve Heart Failure in a Cardiomyocyte-Specific SIRT3 Knockout Mouse Model

Aubrey Cantrell,Quinesha Williams,Jessie Besanson,Heng Zeng,Jian-Xiong Chen

DOI: https://doi.org/10.1124/jpet.542.130331

2024-05-15

Journal of Pharmacology and Experimental Therapeutics

Abstract:ID 130331 Poster Board 542 AIMS: Sirtuin 3 (SIRT3) is a mitochondrial-localized deacetylase associated with aging diseases, including heart failure. Our lab has previously discovered that cardiomyocyte-specific knockout of SIRT3 (SIRT3cKO) in mice leads to heart failure characterized by activation of the ferroptosis cell death pathway. We hypothesized that the ferroptosis inhibitor Ferrostatin-1 (Fer-1) would improve cardiac function in SIRT3cKO mice via improving mitochondrial dysfunction seen in this model. METHODS AND RESULTS: SIRT3loxp wild-type (WT) and SIRT3cKO mice were treated with Ferrostatin-1 via intraperitoneal injection at a dose of 1mg/kg body weight/day for 14 days. Transthoracic echocardiography revealed that SIRT3cKO mice had decreased ejection fraction and fractional shortening, alongside an increased isovolumic relaxation time, isovolumic contraction time, and myocardial performance index, and a decreased E/E' ratio compared to the WT. Treatment with Fer-1 led to an increased ejection fraction and fractional shortening, as well as an improved isovolumic contraction time and myocardial performance index in SIRT3cKO mice. Mitochondrial function analysis demonstrated that SIRT3cKO mice have a decreased mitochondrial membrane potential, which is significantly improved following Fer-1 treatment. Furthermore, SIRT3cKO mice exhibit decreased mitochondrial Complex I and Complex IV activities. Fer-1 treatment increased Complex IV activity in SIRT3cKO mice. Mitochondrial aconitase activity and mitochondrial calcium content were also significantly decreased in SIRT3cKO mice and were ameliorated following Fer-1 treatment. CONCLUSIONS: Fer-1 rescues cardiac dysfunction in SIRT3cKO mice by improving mitochondrial membrane potential and Complex IV activity, as well as normalizing mitochondrial aconitase activity and calcium levels. This study demonstrates for the first time that Fer-1 specifically targets mitochondrial function to reverse cardiac dysfunction, suggesting that Fer-1 may be a potential therapeutic for use in the treatment of heart failure. Funding: This work was supported by the National Institute of General Medical Sciences and National Heart, Lung, and Blood Institute (R01HL151536, JX Chen), the National Heart, Lung, and Blood Institute (R56HL164321, H.Z) and University of Mississippi Medical Center Intramural Research Support Program (IRSP, H.Z.).

pharmacology & pharmacy